Safety of adeno-associated virus gene therapy vectors: a current evaluation
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
An increasing number of strategies for molecular treatment of disease rely on the adeno-associated virus (AAV) as a therapeutic gene delivery vector. One of the most attractive features of this viral DNA vector is the perceived safety of AAV gene delivery. Recent applications in human clinical trials support the safety record established in preclinical trials, with evidence of gene transfer in the absence of cellular immune responses or tissue disturbance. Nevertheless, many aspects of the biology of the wild type AAV and its derivatives are still being explored. While the therapeutic potential of novel recombinant AAV therapeutics appears promising, recent insights suggest aspects of their pharmacokinetics, biodistribution and toxicity that require consideration to achieve the safest application of these molecular medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“Many GMP-grade rAAV facilities have adopted triple-plasmid transfection methods to avoid the use of live virus as reagent at any point in production [15,22].”
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“Large animal models of singleadministration AAV2 treatment to the muscle [42,43] and liver [44] have demonstrated persistent expression for > 3 years; expression in primate lung [45] and canine retina [46] have persisted 6 and 4 months, respectively.”
BackgroundFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“The recruitment of cellular factors for synthesis of a complementary second strand to the virus’ single strand may be the rate-limiting step in expression following rAAV2 therapy [38,39].”
BackgroundMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“A vector design strategy for AAV delivery of small genes, using so-called ‘self-complementary AAV,’ circumvents this requirement [40].”
BackgroundSelf-citationRecombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Self-citationGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“The use of alternative serotypes, however, may overcome this obstacle [79].”
BackgroundInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“Therefore, the details of virus-to-cell contact [7], virus attachment to primary receptors and co-receptors [8,9], endocytosis and trafficking in the endosomal and cytoplasmic compartments [10-12] and nuclear entry are not fully elucidated.”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 3×
“In agreement with previous reports, direct transduction of dendritic cells by rAAV vectors could not be demonstrated [68].”
BackgroundResultSelf-citation
Cited by
Aurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., Nitschko, H., Busch, U., Sing, A., Ehrhardt, A., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.034 · Cited by 490
Stable antibody expression at therapeutic levels using the 2A peptide
Fang, J., Qian, J.-J., Yi, S., Harding, T. C., Tu, G. H., VanRoey, M., & Jooss, K. (2005) · Nature Biotechnology · doi:10.1038/nbt1087 · Cited by 370
Self-citationShort hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown
Taxman, D. J., Moore, C. B., Guthrie, E. H., & Huang, M. T.-H. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-657-3_10 · Cited by 365
De, B. P., Heguy, A., Hackett, N. R., Ferris, B., Leopold, P. L., Lee, J., Pierre, L., Gao, G., Wilson, J. M., & Crystal, R. G. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.003 · Cited by 129
“Use of Nonhuman Primate AAV Serotypes as Gene Transfer Vectors AAV-based vectors are useful for gene transfer because of their low toxicity and persistent transgene expression levels [34–41].”
Lin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33138 · Cited by 88
“rAAV vectors used in clinical gene therapy trials were well tolerated (2, 23).”
Method
Metadata
- Authors
- Monahan, P. E., Jooss, K., & Sands, M. S.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2002-05
- Volume
- 1
- Issue
- 1
- Pages
- 79-91
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2042885067
- Cited by
- 62
- References
- 22
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of adeno-associated virus gene therapy vectors: a current evaluation. https://app.cochat.ai/papers/10.1517/14740338.1.1.79
- The paper
- Monahan, P. E., Jooss, K., & Sands, M. S. (2002). Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.1.1.79
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.